
News|Articles|April 1, 2008
Prostate cancer patients should not be limited to least costly therapy
A men's health group is organizing an online petition to urge Congress to rescind a CMS practice of restricting prostate cancer patients to the least costly drug alternative.
Advertisement
The Centers for Medicare & Medicaid Services should not have decided that prostate cancer patients seeking drug treatments should be given the least costly alternative (LCA). Rather they should be treated according to what the patients' own physician recommends. To protest against CMS' denial of payment for therapies that go beyond LCAs, the Men's Health Policy Center, part of the Men's Health Network (MHN), has set up an
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Model Finds Weight Regain After Stopping Semaglutide or Tirzepatide
2
Study Identifies Patients at Risk for Severe COVID-19 Post-Vaccination
3
Investigational Oral AD109 Reduces Sleep Apnea Severity by 44%
4
Zepbound Lowers Health Care Costs in Older Adults With Obesity
5






































